{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1380021396535275648.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"David C. Klonoff"}],"foaf:familyName":[{"@value":"Klonoff"}],"foaf:givenName":[{"@value":"David C."}]}],"career":[{"institution":{"notation":[{"@value":"Diabetes Research Institute; Mills-Peninsula Health Services, San Mateo, CA, USA"}]}}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1360021396535275648","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1177/1932296819832661"},{"@type":"URI","@value":"http://journals.sagepub.com/doi/pdf/10.1177/1932296819832661"},{"@type":"URI","@value":"http://journals.sagepub.com/doi/full-xml/10.1177/1932296819832661"}],"notation":[{"@value":"The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1177/1932296819832661_J3Ot7IjxMwGvKK3s6UQLBCCQ0rW"}]}